PTCT vs. TGTX, CCXI, ZGNX, FTSV, SAGE, CTLT, ELAN, INSM, ROIV, and ASND
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include TG Therapeutics (TGTX), ChemoCentryx (CCXI), Zogenix (ZGNX), Forty Seven (FTSV), Sage Therapeutics (SAGE), Catalent (CTLT), Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.
PTC Therapeutics (NASDAQ:PTCT) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
PTC Therapeutics presently has a consensus price target of $35.67, indicating a potential downside of 1.91%. TG Therapeutics has a consensus price target of $29.83, indicating a potential upside of 83.03%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than PTC Therapeutics.
TG Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500.
In the previous week, PTC Therapeutics had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 8 mentions for PTC Therapeutics and 3 mentions for TG Therapeutics. PTC Therapeutics' average media sentiment score of 0.87 beat TG Therapeutics' score of 0.62 indicating that PTC Therapeutics is being referred to more favorably in the media.
58.6% of TG Therapeutics shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 9.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
TG Therapeutics has a net margin of 14.24% compared to PTC Therapeutics' net margin of -62.45%. TG Therapeutics' return on equity of 31.34% beat PTC Therapeutics' return on equity.
TG Therapeutics received 110 more outperform votes than PTC Therapeutics when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 61.83% of users gave PTC Therapeutics an outperform vote.
Summary
TG Therapeutics beats PTC Therapeutics on 15 of the 18 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
